Key Takeaways
- Guidance cut, but the reset is specific: FY23 EBITDA guided to ₹1,100 crore, down from earlier expectations, driven almost entirely by a sharp, global slowdown in dyes and pigments. The agrochemical and additive businesses remain strong.
- A maintenance shutdown masked the underlying volume: Q2 volumes were substantially flat because a three-week maintenance shutdown at Jhagadia was pulled forward into a demand-soft patch. Without it, volume growth would have been only 2-3% better, confirming the demand weakness is real.
- The long-term growth story is intact and funded: Management reiterated a 25% EBITDA CAGR for FY24 and FY25, targeting ₹1,700 crore, backed by ₹3,000 crore in collective capex and a direct conversion of gross profit to EBITDA as new capacities ramp.
- The pharma demerger is closing: NCLT approval is in hand and the listing of Aarti Pharmalabs is expected in December 2022, removing a structural overhang.
- What to watch next quarter: Whether the dye stuff recovery actually materialises in Q3 as management hopes, the pace of commissioning for the third long-term contract, and any further softening in raw material prices that could provide a lagged benefit to exports.
The Dyes & Pigments Downturn
- The core problem: A global slowdown in dyes and pigments, driven by destocking, consolidation among pigment players, and weak end-user industries like textile printing ink and automotive coatings, is the primary reason for the lowered FY23 guidance.
- Split recovery timeline: Dye stuff demand is expected to recover first, possibly as early as Q3, because the impact started earlier. Pigment demand, which weakened later, may take until Q4 to recover. Full normalization for both segments is not expected until FY25.
- Geographic split: The pigment impact is global, while the dyes impact is felt more within India, where most dyes intermediates are consumed domestically alongside some exports.
- The shutdown amplified the weakness: A three-week maintenance shutdown at Jhagadia was taken partly because of the demand pressure itself, which further suppressed volumes for Nitro Toluene, PDA and Chloro aniline in the quarter.
Rajendra Gogri: "I think the dyes and pigments segments are weak. So, I think that will continue in the second half also. That is the main reason for lower guidance. Hopefully the things start recovering in Q4 and the next year, we don't have any impact of this slowdown in this segment."
The Growth Engine: Long-Term Contracts & Capex
- Three contracts, three stages: The first long-term contract is scaling as expected and should hit ~70% utilisation next financial year. The second is ramping up in a phased manner and generating EBITDA per contract terms. The third is on track for commissioning by the end of Q3 FY23.
- The capex cycle is not slowing down: Management explicitly stated it is not looking at any slowdown in capex despite global concerns, citing long-term product visibility. Collective capex for FY24 and FY25 is expected around ₹3,000 crore.
- Capitalisation wave incoming: Around ₹1,000 crore of capital work-in-progress is set to be capitalised in H2 FY23 alone, covering the third contract, specialty chemical blocks and Nitro Chloro Benzene. Most of the remaining CWIP, barring the ethylation loop, will be capitalised by Q2 FY24.
- New initiatives beyond FY25: The ethylation capacity at Dahej is being tripled with a ₹200 crore investment and will commission in H1 FY25. Beyond that, Chloro Toluene, multipurpose plants and other new initiatives will start commissioning from H2 FY25 into FY26, with Chloro Toluene expected to deliver a higher EBITDA per kg.
Rajendra Gogri: "We have a long-term visibility of the products. So as such, we are not looking at any slowdown in the CapEx."
Operating Leverage & Margin Mechanics
- The gross-profit-to-EBITDA bridge: Management expects a direct transfer of gross profit to EBITDA over the next two years as new capacities ramp up, because fixed costs and employee costs are not expected to increase much beyond normal increments. This operating leverage is the engine behind the 25% CAGR target.
- Raw material tailwinds are emerging: Benzene, Toluene and Phthalic Anhydride prices are coming down. While domestic pass-through mechanisms have a quarterly or monthly lag, exports have a three-month lag, meaning Aarti will get a benefit on the export side as lower costs flow through.
- Freight costs are easing: Freight rates are coming down in Q3, though the impact on reported profitability is muted because most larger contracts have freight pass-through clauses. The benefit will show up more in working capital than in margins.
- Currency provides a structural, if limited, boost: Rupee depreciation added around ₹8-10 crore to EBITDA in Q2, but the benefit is capped because exports are hedged with forwards over the next three years. [7-8]
Rajendra Gogri: "In the next two years, we expect direct transfer of gross profit to EBITDA because we don't expect much of fixed costs or employee cost increase in the next couple of years, other than the normal increments. So that's why we are targeting a 25% CAGR."
Nitric Acid: A Strategy Still Taking Shape
- No near-term impact, but the clock is ticking: Management does not expect a significant nitric acid impact in H2 FY23 or FY24, citing subdued overall demand and new capacity coming online. Ammonia prices at ~$1,000 kept nitric acid prices elevated in H1 due to the Ukraine war, but that pressure is easing.
- The concentration plant is ordered: An order for a concentrated nitric acid plant has been placed, with commissioning expected in Q4 FY24. This is one piece of a broader strategy.
- The comprehensive strategy is delayed: Management had planned to share a full nitric acid strategy on this call but said it needs more time. When an analyst asked what visibility exists that new capacity volumes will be shared with Aarti, the question was deferred to the future strategy disclosure.
Rajendra Gogri: "The comprehensive nitric strategy is what we were planning to share in this call but it may take some more time and we'll come out with the comprehensive strategy."
Financials: A Quarter of Headwinds
- Profit after tax was muted: Higher finance costs, including a negative FOREX mark-to-market impact of ₹20 crore, and an increase in depreciation in line with new capacities added, weighed on PAT despite stable absolute EBITDA.
- Other expenses spiked on export mix: Other expenses rose sharply both QoQ and YoY because the export share increased to ~50% from a typical 40-45%, and higher freight costs on exports pushed expenses up. Some maintenance-related costs also contributed on a YoY basis.
- Dicamba remains a drag: The Dicamba intermediate facility is running at only ~25% utilisation (720 tonnes per quarter) and is currently not at breakeven. Utilisation is expected to progressively increase from H2 onwards.
- Working capital has room to shrink: Management sees potential to reduce working capital on a value basis because freight rates and raw material prices are showing softness, though the number of days should remain similar.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 EBITDA | Target around ₹1,100 crore | FY23 |
| FY24 & FY25 EBITDA CAGR | 25% CAGR, targeting ₹1,700 crore by FY25 | FY24-FY25 |
| Collective capex | Around ₹3,000 crore | FY24 and FY25 |
| Third long-term contract commissioning | Construction progressing well | End of Q3 FY23 |
| First long-term contract utilisation | Ramp to ~70% utilisation | Next financial year (FY24) |
| CWIP capitalisation | ~₹1,000 crore to be capitalised | H2 FY23 |
| Ethylation capacity commissioning | Triple capacity at Dahej SEZ, ~₹200 crore investment | H1 FY25 |
| Concentrated nitric acid plant commissioning | Order placed | Q4 FY24 |
| Dyes & pigments normalization | Both segments to contribute normally to volumes | By FY25 |
| Pharma demerger listing | Aarti Pharmalabs Limited listing | December 2022 |
| New initiatives commissioning | Chloro Toluene, multipurpose plants, etc. | H2 FY25 into FY26 |
| Comprehensive FY27 guidance | To be provided | Next couple of quarters |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹1,847 cr, +29% YoY; exports contributed over 50% of total revenues |
| EBITDA | ₹267 cr, +5% YoY; +30% YoY after normalising for ₹52 cr shortfall fees in Q2 FY22 |
| Profit after tax | ₹124 cr |
| Negative FOREX mark-to-market impact | ₹20 cr, impacting PAT |
| FY23 EBITDA guidance | ~₹1,100 cr |
| EBITDA CAGR guidance for FY24 & FY25 | ~25% |
| FY25 EBITDA target | ~₹1,700 cr, based on 25% CAGR from FY23 |
| Value-added products share | 78% of sales |
| Nitrochlorobenzene production | 20,276 MT |
| Nitro-Toluene production | 4,954 MT |
| PDA volumes | ~242 tons per month |
| Dicamba intermediate utilisation | ~25% (720 tonnes per quarter vs. 2,400 tonnes capacity); currently not breakeven |
| Ethylation capacity utilisation (Dahej SEZ) | ~90% |
| H1 FY23 CAPEX | ₹577 cr |
| FY23 CAPEX target | ~₹1,100 to 1,200 cr |
| Collective CAPEX for FY24 and FY25 | ~₹3,000 cr |
| Maintenance shutdown impact on profitability | ~₹15 cr |
| Currency benefit in Q2 | ~₹8 cr to ₹10 cr |
| R&D pipeline | 50+ products in Chemicals at various stages |